The present invention relates to a triple transgenic animal model for
Alzheimer's disease as well as to methods for generating multi-transgenic
animals. The present invention also relates to methods for screening
biologically active agents potentially useful for treating and/or
ameliorating Alzheimer's disease (AD) or AD-type pathologies,
compositions useful for treating AD or AD-type pathologies, and methods
of treating AD patients.